Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives op

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adul

The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with ​a c

https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-fi

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential ne

Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billio

Abogen said its lead drug has potential to transform the treatment landscape for patients with autoi

Chinese biotech company Abogen ​said on Friday it signed ‌a licensing deal worth about $7.8 billion

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

On September 29, 2026, Novartis AG (NVS) shares fell 0.8% today, trading at $145.71. The stock has f

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG (NYSE: NVS). In

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpo

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CS

Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The co

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding i

Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are bo

Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acqui

Novartis has halted development of an experimental drug ​for amyotrophic lateral sclerosis after it

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper dr

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure,

Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective i

Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sh

HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price t

Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, a

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne

Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering

AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical

U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, a

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Predict

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impac

NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III L

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s

Europe closed mixed as the AfD's Saxony-Anhalt landslide and $97 Brent lifted bond yields, and W

Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascul

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effect

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutini

U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext In

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's str

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly

Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors